Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
SAN DIEGO, May 03, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its first quarter financial and operating results after the close of U.S. financial markets on Wednesday, May 10, 2017. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | ||
| Date: | May 10, 2017 | |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) | |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) | |
| Passcode: | 15138572 | |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section | |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
